drug
EPIRUBICIN HYDROCHLORIDE
Marketedupdated 3mo agoby $AMRX Amneal Pharmaceuticals, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Breast Cancer
all catalysts(7)
approval · 7
Oct 22, 2007
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Dec 20, 2014
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Jan 27, 2020
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Jan 27, 2020
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Jan 30, 2026
approval
EPIRUBICIN HYDROCHLORIDE — FDA approval
EPIRUBICIN HYDROCHLORIDE
→
Trials studying EPIRUBICIN HYDROCHLORIDE
- phase2Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
- phase2A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that